EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer

Jacob Hanna iD, Melinda Z Fu, Berk Inan, David Guevara iD, Lucille Lannan, Disha Patel, Mahdi Hemmati Ghavshough, David Golombos, Thomas Jang iD, Saum Ghodoussipour, Vignesh T Packiam

BJUI Compass · 2026-05 · 7 (5)

DOI: 10.1002/bco2.70215 ↗

At a glance

Journal article in BJUI Compass, published online on 2026-05-14. Written by Jacob Hanna and 10 co-authors. Institution: Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA. Cited 1 times so far (Crossref); 20 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCI NIH HHS, National Cancer Institute.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objectives

This study aimed to evaluate the time toxicity of intravesical BCG compared to sequential intravesical gemcitabine and docetaxel (Gem/Doce) for non–muscle‐invasive bladder cancer (NMIBC). Patients and Methods After IRB approval, we retrospectively reviewed patients with NMIBC treated with BCG or Gem/Doce between 2022 and 2025 at our institution. Medical records were used to calculate time for intravesical therapy, office visits, transurethral resection of bladder tumour (TURBT) and emergency department encounters. Continuous variables were compared using the Wilcoxon rank sum test with Hodges–Lehmann estimates.

Results

Of 133 patients, 86 received BCG (65%) and 47 Gem/Doce (35%). Patients with BCG were more likely treatment naïve compared to those with Gem/Doce (77% vs 55%, p = 0.018). Median time per instillation was 179 min for BCG compared to 192 min for Gem/Doce (Hodges–Lehmann shift +27 min, 95% CI 4 to 57; p = 0.02). Median TURBT time, office visit time and emergency department visit time were similar between groups (all p > 0.05). Over the first six instillations, the cumulative difference was 306 min (+5.1 h, p < 0.001).

Conclusion

Gem/Doce requires a greater time investment than BCG. As effective NMIBC therapies expand, time toxicity should be considered alongside oncologic outcomes.

Subjects

Author keywords

BCGbladder cancerdocetaxelgemcitabineintravesical therapynon–muscle‐invasive bladder cancertime toxicity

Authors and institutions

  • Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA.
  • Section of Urologic Oncology Rutgers Cancer Institute New Brunswick New Jersey USA.

ORCID profiles: Jacob Hanna, David Guevara, Thomas Jang

Funding

  • NCI NIH HHS
  • National Cancer Institute

Cite

APA

Hanna, J., Fu, M. Z., Inan, B., Guevara, D., Lannan, L., Patel, D., Hemmati Ghavshough, M., Golombos, D., Jang, T., Ghodoussipour, S., & Packiam, V. T. (2026). Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer. BJUI Compass, 7(5). https://doi.org/10.1002/bco2.70215

Vancouver

Hanna J, Fu MZ, Inan B, Guevara D, Lannan L, Patel D, et al. Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer. BJUI Compass. 2026;7(5). doi:10.1002/bco2.70215

BibTeX
@article{Hanna2026,
  author = {Hanna, Jacob and Fu, Melinda Z and Inan, Berk and Guevara, David and Lannan, Lucille and Patel, Disha and Hemmati Ghavshough, Mahdi and Golombos, David and Jang, Thomas and Ghodoussipour, Saum and Packiam, Vignesh T},
  title = {Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer},
  journal = {BJUI Compass},
  year = {2026},
  volume = {7},
  number = {5},
  doi = {10.1002/bco2.70215}
}
Start for free →